Free tool
FAERS Monitor: Vytorin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021687 or its brand name (Vytorin, Ezetimibe, Simvastatin). Reports on generic versions are filed under their own applications.
Reports
15,138
Serious
9,500
63% of reports
Hospitalization
4,785
Death reported
857
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,013
- drug ineffective821
- fatigue777
- dizziness734
- pain708
- myalgia675
- dyspnoea647
- diarrhoea605
- asthenia604
- headache566
- pain in extremity550
- arthralgia533
- myocardial infarction518
- weight decreased504
- fall476
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 627 |
| 2006 | 949 |
| 2007 | 1,301 |
| 2008 | 1,554 |
| 2009 | 1,189 |
| 2010 | 1,679 |
| 2011 | 1,130 |
| 2012 | 987 |
| 2013 | 801 |
| 2014 | 830 |
| 2015 | 912 |
| 2016 | 751 |
| 2017 | 563 |
| 2018 | 447 |
| 2019 | 407 |
| 2020 | 250 |
| 2021 | 197 |
| 2022 | 132 |
| 2023 | 97 |
| 2024 | 98 |
| 2025 | 110 |
| 2026 | 87 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,021 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myalgiaSignal | 675 | 5.5 | 5.1 | 2,513 |
| myocardial infarctionSignal | 518 | 4.1 | 3.8 | 1,234 |
| pain in extremitySignal | 550 | 2.6 | 2.4 | 545 |
| weight decreasedSignal | 504 | 2.5 | 2.3 | 462 |
| astheniaSignal | 604 | 2.2 | 2.1 | 417 |
| dizzinessSignal | 734 | 2.0 | 1.9 | 401 |
| fall | 476 | 2.0 | 1.8 | 236 |
| arthralgia | 533 | 1.8 | 1.6 | 186 |
| nausea | 1,013 | 1.8 | 1.7 | 358 |
| pain | 708 | 1.6 | 1.5 | 164 |
| dyspnoea | 647 | 1.6 | 1.5 | 144 |
| fatigue | 777 | 1.4 | 1.3 | 87 |
| diarrhoea | 605 | 1.3 | 1.2 | 44 |
| headache | 566 | 1.3 | 1.2 | 30 |
| drug ineffective | 821 | 0.9 | 0.8 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.